Company Overview and News

 
Sakthi Sugars Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Government should look to build 5 mt buffer of sugar stock: Sakthi Sugars

2018-03-21 moneycontrol
Sugar stocks will be in focus today as the government has scrapped export duty of raw and refined sugar to boost shipments. In an interview to CNBC-TV18, M Manickam, Executive VC of Sakthi Sugars spoke at length about the sector.
Upvote Downvote

 
No more SAP for TN sugar mills

2018-03-15 thehindubusinessline
Shares of Tamil Nadu-based sugar producers such as EID Parry, Ponni Sugars (Erode), Rajshree Sugars and Chemicals, Sakthi Sugars and Thiru Arooran Sugars may see buying interest, as the TN government has decided to move away from State Advisory Price over and above the fair and remunerative price for sugarcane. In the Budget speech on Thursday, the Finance Minister said the state has decided to switch over to the revenue share price fixation model.
Upvote Downvote

 
Govt is taking steps to stabilise the sugar price: Sakthi Sugars

2018-03-06 moneycontrol
Sugar production is already on the higher side and at ISMA's board meet on March 7 it could head further north.
Upvote Downvote

 
Market Update: CNX Metal outshines led by JSPL, Tata Steel; Vedanta top gainer; IndusInd, Yes Bank up 2%

2018-03-06 moneycontrol
The Indian benchmark indices were trading on a positive note on Tuesday morning with the Nifty gaining 68 points at 10,462 while the Sensex jumped 233 points.
Upvote Downvote

 
Sakthi Sugars Limited - Updates

2018-02-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Sakthi Sugars Limited - Financial Result Updates

2018-02-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Global cues, banks drag Sensex 310 pts, Nifty below 10,700; midcaps recover sharply

2018-02-05 moneycontrol
Investors sentiment remained weak on Monday as benchmark indices extended sell-off for the fifth consecutive session, dented by global weakness on worries that US inflation could rise faster than expectations.
Upvote Downvote

 
Market Update: Nifty Pharma outperforms with DRL top Nifty gainer; TCS falls 3%, SBI most active

2017-12-14 moneycontrol
The Indian benchmark indices on Thursday afternoon were trading on a negative note with the Nifty down 9 points or 0.09 percent while the Sensex shedding 46 points and was trading at 33012.
Upvote Downvote

 
Market Update: TCS, UPL fall 2%, Glenmark Pharma hits 52-week low; Tata Comm, RIL most active

2017-12-14 moneycontrol
The Indian benchmark indices on Thursday afternoon were trading on a negative note with the Nifty up 19 points or 0.19 percent while the Sensex shedding 80 points and was trading at 32972.
Upvote Downvote

 
Market Update: SBI, PNB, YES Bank up 2% as Bank Nifty outperforms; Hero Moto, Wipro top losers

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty up 1 point or 0.01 percent while the Sensex shed 25 points and was trading at 32838.
Upvote Downvote

 
Market Update: RIL, Bharti Airtel top Nifty gainers; Eicher Motors down over 2%, Infosys most active

2017-12-05 moneycontrol
The Indian benchmark indices on Tuesday afternoon were still trading on a negative note with the Nifty down 42 points or 0.42 percent while the Sensex shed 141 points and was trading at 32727.
Upvote Downvote

 
Market Update: Sun Pharma falls over 4%, Lupin, RComm hits 52-week low; TCS most active

2017-11-15 moneycontrol
The Indian benchmark indices on Wednesday afternoon were in bear grip with the Nifty down 58 points or 0.57 percent while the Sensex shed 155 points at 32782.
Upvote Downvote

 
Market Update: Biocon zooms over 7% as midcaps outperform; BPCL, HPCL top gainers, ONGC down 3%

2017-11-15 moneycontrol
The Indian benchmark indices on Wednesday afternoon were still trading weak with the Nifty down 28 points or 0.28 percent while the Sensex shed 74 points at 32867.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...